Icon (NASDAQ:ICLR) & MindWalk (NASDAQ:HYFT) Head to Head Contrast

Icon (NASDAQ:ICLR) and MindWalk (NASDAQ:HYFT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Institutional & Insider Ownership

95.6% of Icon shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 44.0% of Icon shares are owned by company insiders. Comparatively, 6.8% of MindWalk shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Icon and MindWalk”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25 billion	1.53	$229.34 million	$4.26	38.70
MindWalk	$11.24 million	5.49	-$10.11 million	($0.22)	-6.00

Icon has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Icon and MindWalk’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
MindWalk	-89.65%	-92.61%	-54.15%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Icon and MindWalk, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2	7	7	1	2.41
MindWalk	2	0	2	1	2.40

Icon presently has a consensus target price of $170.40, suggesting a potential upside of 3.37%. MindWalk has a consensus target price of $5.00, suggesting a potential upside of 278.79%. Given MindWalk’s higher possible upside, analysts plainly believe MindWalk is more favorable than Icon.

Volatility and Risk

Icon has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Summary

Icon beats MindWalk on 12 of the 14 factors compared between the two stocks.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.